Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study
Clinical Trial Information
Trial Contact: See Principal Investigator
Test whether amyloid PET imaging will lead to a ≥ 30% change between intended and actual patient management within 90 days in a composite measure consisting of the following: a) AD drug therapy; b) Other drug therapy; or c) Counseling about safety and future planning.
Medicare beneficiary 65 years of age or older with diagnosis of MCI or dementia, according to DSM-IV and/or National Institutes 4.1.3of Aging-Alzheimer’s Association criteria, verified by a dementia specialist within 24 months